Role of Sodiumglucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
Weight loss plateaus during tirzepatide treatment result from multiple interconnected physiological and behavioral factors
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
It significantly raises the risk of cardiovascular events, including coronary heart disease, heart failure, stroke, and mortality (Carey et al
These substances restore facial volume even in patients with pronounced atrophy but are generally unsuitable for lips and superficial wrinkles
From Obesity to Metabolic Health: Why Retatrutide Is a Game-Changer Abstract Obesity and type 2 diabetes have become global health crises, fueling complications such as cardiovascular disease, fatty liver disease, and metabolic syndrome